A compound of Formula, or a pharmaceutically acceptable salt or ester thereof; wherein: X 1 is CH or N; X 2, X 3, X 4, X 5, X 6 and X 7 independently are NR 4, CH 2, CHQ or C 2, provided that: (i) zero, one or two of X 2, X 3, X 4, X 5, X 6 and X 7 are NR 4; (ii) when X 1 is N, both of X 2 and X 7 are not NR 4; (iii) when X 1 is N, X 3 and X 6 are not NR 4; and (iv) when X 1 is CH and two of X 2, X 3, X 4, X 5, X 6 and X 7 are NR 4, the two NR 4 are located at adjacent ring positions or are separated by two or more other ring positions; A and V independently are H, halo, azido, -CN, -CF 3, -CONR 1 R 2, -NR 1 R 2, -SR 2, -OR 2, -R 3, -W, -L-W, -W 0, or -L-N -W 0; each Q is independently halo, azido, -CN, -CF 3, -CONR 1 R 2, -NR 1 R 2, -SR 2, -OR 2, -R 3, -W, -L-W, -W 0, or -L-N -W 0; in each -NR 1 R 2, R 1 and R 2 together with N may form an optionally substituted azacyclic ring, optionally containing one additional heteroatom selected from N, O and S as a ring member; R 1 is H or C1-C6 alkyl, optionally substituted with one or more halogens, or =O; R 2 is H, or C1-C10 alkyl, C1-C10 heteroalkyl, C2-C10 alkenyl, or C2-C10 heteroalkenyl, each of which may be optionally substituted with one or more halogens, =O, or an optionally substituted 3-7 membered carbocyclic or heterocyclic ring; R 3 is an optionally substituted C1-C10 alkyl, C2-C10 alkenyl, C5-C10 aryl, or C6-C12 arylalkyl, or a heteroform of one of these, each of which may be optionally substituted with one or more halogens, =O, or an optionally substituted 3-6 membered carbocyclic or heterocyclic ring; each R 4 is independently H, or C1-C6 alkyl; or R4 may be -W, -L-W or -L-N -W 0; each R is independently H or C1-C6 alkyl; R 7 is H and R 8 is C1-C10 alkyl, C1-C10 heteroalkyl, C2-C10 alkenyl, or C2-C10 heteroalkenyl, each of which may be optionally substituted with one or more halogens, =O, or an optionally substituted 3-7 membered carbocyclic or heterocyclic ring; or in -NR 7 R 8, R 7 and R 8 together with N may form an optionally substituted azacyclic ring, optionally containing an additional heteroatom selected from N, O and S as a ring member; m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3, 4, or 5; L is a C1-C10 alkylene, C1-C10 heteroalkylene, C2-C10 alkenylene or C2-C10 heteroalkenylene linker, each of which may be optionally substituted with one or more substituents selected from the group consisting of halogen, oxo (=O), or C1-C6 alkyl; W is an optionally substituted 4-7 membered azacyclic ring, optionally containing an additional heteroatom selected from N, O and S as a ring member; and W 0 is an optionally substituted 3-4 membered carbocyclic ring, or a C1-C6 alkyl group substituted with from 1 to 4 fluorine atoms, for use in treating multiple sclerosis in a subject. X 1 is CH or N; X 2, X 3, X 4, X 5, X 6 and X 7 independently are NR 4, CH 2, CHQ or C 2, provided that: (i) zero, one or two of X 2, X 3, X 4, X 5, X 6 and X 7 are NR 4; (ii) when X 1 is N, both of X 2 and X 7 are not NR 4; (iii) when X 1 is N, X 3 and X 6 are not NR 4; and (iv) when X 1 is CH and two of X 2, X 3, X 4, X 5, X 6 and X 7 are NR 4, the two NR 4 are located at adjacent ring positions or are separated by two or more other ring positions; A and V independently are H, halo, azido, -CN, -CF 3, -CONR 1 R 2, -NR 1 R 2, -SR 2, -OR 2, -R 3, -W, -L-W, -W 0, or -L-N -W 0; each Q is independently halo, azido, -CN, -CF 3, -CONR 1 R 2, -NR 1 R 2, -SR 2, -OR 2, -R 3, -W, -L-W, -W 0, or -L-N -W 0; in each -NR 1 R 2, R 1 and R 2 together with N may form an optionally substituted azacyclic ring, optionally containing one additional heteroatom selected from N, O and S as a ring member; R 1 is H or C1-C6 alkyl, optionally substituted with one or more halogens, or =O; R 2 is H, or C1-C10 alkyl, C1-C10 heteroalkyl, C2-C10 alkenyl, or C2-C10 heteroalkenyl, each of which may be optionally substituted with one or more halogens, =O, or an optionally substituted 3-7 membered carbocyclic or heterocyclic ring; R 3 is an optionally substituted C1-C10 alkyl, C2-C10 alkenyl, C5-C10 aryl, or C6-C12 arylalkyl, or a heteroform of one of these, each of which may be optionally substituted with one or more halogens, =O, or an optionally substituted 3-6 membered carbocyclic or heterocyclic ring; each R 4 is independently H, or C1-C6 alkyl; or R4 may be -W, -L-W or -L-N -W 0; each R is independently H or C1-C6 alkyl; R 7 is H and R 8 is C1-C10 alkyl, C1-C10 heteroalkyl, C2-C10 alkenyl, or C2-C10 heteroalkenyl, each of which may be optionally substituted with one or more halogens, =O, or an optionally substituted 3-7 membered carbocyclic or heterocyclic ring; or in -NR 7 R 8, R 7 and R 8 together with N may form an optionally substituted azacyclic ring, optionally containing an additional heteroatom selected from N, O and S as a ring member; m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3, 4, or 5; L is a C1-C10 alkylene, C1-C10 heteroalkylene, C2-C10 alkenylene or C2-C10 heteroalkenylene linker, each of which may be optionally substituted with one or more substituents selected from the group consisting of halogen, oxo (=O), or C1-C6 alkyl; W is an optionally substituted 4-7 membered azacyclic ring, optionally containing an additional heteroatom selected from N, O and S as a ring member; and W 0 is an optionally substituted 3-4 membered carbocyclic ring, or a C1-C6 alkyl group substituted with from 1 to 4 fluorine atoms, for use in treating multiple sclerosis in a subject.